NEWS

Leiden, 15 October 2021 – BIMINI Biotech, an innovative therapeutics start-up that develops new cancer drugs, raised an investment of €250,000. The seed funding is provided by Libertatis Ergo Holding B.V. (LEH), a wholly owned subsidiary of Leiden University which supports and invests in spinout… Lees verder »BIMINI Biotech closes seed investment with Libertatis Ergo Holding

Leiden, 26 November 2020 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has secured an investment of €200,000 from proof-of-concept fund UNIIQ to further develop its technology. The company aims to use the growth hormone receptor to uniquely inhibit cancer cell… Lees verder »UNIIQ invests €200,000 in novel cancer therapeutics startup BIMINI Biotech

BIMINI Biotech is one of the 10 winners of the Academic Startup Competition 2020 and is now entitled to use the title ‘Best Academic Startup of 2020’ for the coming year. The other winning startups are DeNoize, Digi Bio, IamFluidics, Kaminari Medical, Lusoco, NC Biomatrix,… Lees verder »Utrecht University spinoff hits Top 10 list of most ground-breaking academic startups

BIMINI Biotech has been awarded the Eureka INNOWIDE grant of €60.000 to set up a collaborative (pre-) clinical network of expert parties in India and accelerate cost-effective drug development. Together with our expert partner TheraIndx, we will make these initial steps for our lead compound.… Lees verder »BIMINI Biotech has been awarded the INNOWIDE grant

BIMINI Biotech has been awarded the NWO Take-off Phase 1 grant (€40.000) in collaboration with the Universitair Medisch Centrum Utrecht (UMCU) to perform an extensive feasibility study for BIMINI’s lead compound. The aim of the grant is to stimulate entrepreneurship and valorisation of breakthrough innovations… Lees verder »BIMINI Biotech has been awarded the NWO Take-off Phase 1